Things were not looking up for the med tech industry in 2013. A report released today by EP Vantage, "MedTech 2013 In Review," showed worsening market conditions for devicemakers last year, with mergers and acquisitions taking the biggest hit.
New guidance just published by Health Canada shows it will institute a three-level ranking system for plants divided by high-risk and low-risk products, rather than issue a simple "compliant" or "non-compliant" designation.
IT consulting giant Accenture has purchased Octagon Research Solutions, looking to offer pharma companies help with streamlining their regulatory filings.
Vertex ($VRTX) has taken another step toward building a global franchise for treating cystic fibrosis. European regulatory advisers backed approval of the trailblazing drug Kalydeco for a subset of patients with the genetic disorder, paving the way for a likely go-ahead to market the drug in the EU.
For 2012, contract manufacturers should brace for an increase in requests for bioanalytical testing, consulting, high-potency compound and regulatory support services. But they should be able to
Drug regulators in the U.S and Europe are becoming fast friends. Officials are talking more, according to regulator-panelists at a town hall gathering held this week at the ISPE annual meeting in San